OVERLOOK MEDICAL CENTER
- Type
- Teaching hospital
- Where
- Summit, NJ
- Medicare CCN
- 310051
- Received
- $399,592 in 101 records, 2019 ($31,359 general, $368,232 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 23 | $31,359 |
| 2019 | Research payment | 78 | $368,232 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 25 | $143,467 | 2019 |
| Genentech, Inc. | 20 | $136,307 | 2019 |
| Penumbra, Inc. | 20 | $51,727 | 2019 |
| TESARO, Inc. | 3 | $17,919 | 2019 |
| Genentech USA, Inc. | 4 | $8,750 | 2019 |
| Boston Scientific Corporation | 4 | $8,717 | 2019 |
| Roche Products Limited | 4 | $6,250 | 2019 |
| ACELL, INC. | 3 | $4,059 | 2019 |
| ZOLL Circulation Inc | 1 | $4,010 | 2019 |
| E.R. Squibb & Sons, L.L.C. | 2 | $3,750 | 2019 |
| Merck Sharp & Dohme LLC | 3 | $3,596 | 2019 |
| Merit Medical Systems Inc | 1 | $3,000 | 2019 |
| CSL Behring | 3 | $2,594 | 2019 |
| W. L. Gore & Associates, Inc. | 1 | $1,500 | 2019 |
| Janssen Pharmaceuticals, Inc | 2 | $1,400 | 2019 |
| Emmaus Medical, Inc. | 1 | $1,000 | 2019 |
| MDD US Operations, LLC | 2 | $1,000 | 2019 |
| Stryker Corporation | 1 | $500 | 2019 |
| Hollister Incorporated | 1 | $42 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 78 | $368,232 |
| Space rental or facility fees (teaching hospital only) | 13 | $20,450 |
| Gift | 1 | $4,010 |
| Grant | 1 | $3,000 |
| Education | 5 | $2,856 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $1,000 |
| Food and Beverage | 1 | $42 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-18 | Penumbra, Inc. | $1,000 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | PRONTO | 2019 |
| 2019-12-16 | Boston Scientific Corporation | $2,625 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE III | 2019 |
| 2019-12-13 | W. L. Gore & Associates, Inc. | $1,500 | Education | Cash or cash equivalent | DUALMESH Biomaterial Device, Devices | 2019 | |
| 2019-12-12 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-12-11 | Penumbra, Inc. | $911 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-12-03 | Genentech, Inc. | $5,932 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2019 |
| 2019-11-22 | Genentech, Inc. | $8,439 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | A PHASE III STUDY IN COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN BRAFWT MELANOMA PATIENTS | 2019 |
| 2019-11-20 | Bayer Healthcare Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-11-05 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2019 |
| 2019-11-04 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | A PHASE III STUDY IN COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN BRAFWT MELANOMA PATIENTS | 2019 |
| 2019-11-04 | Bayer Healthcare Pharmaceuticals Inc. | $1,070 | Research payment | Cash or cash equivalent | Non-Covered | Ph III Copanlisib+Rituximab in relapsed iNHL | 2019 |
| 2019-10-31 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-10-31 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-10-24 | Genentech, Inc. | $14,590 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2019 |
| 2019-10-21 | Boston Scientific Corporation | $3,123 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE III | 2019 |
| 2019-10-17 | Penumbra, Inc. | $911 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-10-16 | ACELL, INC. | $252 | Education | Cash or cash equivalent | 2019 | ||
| 2019-10-16 | ACELL, INC. | $59 | Education | Cash or cash equivalent | 2019 | ||
| 2019-10-15 | TESARO, Inc. | $3,895 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | 2019 |
| 2019-10-09 | Penumbra, Inc. | $1,000 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | PRONTO | 2019 |
| 2019-10-08 | Genentech, Inc. | $1,488 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2019 |
| 2019-10-03 | Penumbra, Inc. | $500 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-09-26 | CSL Behring | $550 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-09-25 | Penumbra, Inc. | $1,822 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-09-12 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2019 |
| 2019-09-11 | Genentech USA, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Activase Biological, Metabolism & Primary Care | 2019 | |
| 2019-09-06 | Merck Sharp & Dohme LLC | $96 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-09-04 | Emmaus Medical, Inc. | $1,000 | Education | Cash or cash equivalent | Endari Drug, Sickle Cell | 2019 | |
| 2019-08-28 | Penumbra, Inc. | $1,000 | Research payment | Cash or cash equivalent | Penumbra SMART Coil Device, Neurointervention | SMART Registry | 2019 |
| 2019-08-28 | Penumbra, Inc. | $675 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-08-28 | Penumbra, Inc. | $250 | Research payment | Cash or cash equivalent | Penumbra SMART Coil Device, Neurointervention | SMART Registry | 2019 |
| 2019-08-23 | CSL Behring | $44 | Education | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | 2019 | |
| 2019-08-19 | Roche Products Limited | $1,000 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | MORPHEUS PANCREATIC | 2019 |
| 2019-08-15 | TESARO, Inc. | $11,774 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | 2019 |
| 2019-07-26 | Bayer Healthcare Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Non-Covered | Ph III Copanlisib+Rituximab in relapsed iNHL | 2019 |
| 2019-07-25 | Penumbra, Inc. | $1,485 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-07-18 | Penumbra, Inc. | $7,000 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | PRONTO | 2019 |
| 2019-07-17 | Hollister Incorporated | $42 | Food and Beverage | In-kind items and services | CERAPLUS Device, OSTOMY | 2019 | |
| 2019-07-15 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-07-12 | Genentech, Inc. | $16,234 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2019 |
| 2019-07-08 | MDD US Operations, LLC | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | APOKYN Drug, Neurology | 2019 | |
| 2019-07-08 | MDD US Operations, LLC | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Xadago Drug, Neurology | 2019 | |
| 2019-07-05 | Roche Products Limited | $250 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | MORPHEUS PANCREATIC | 2019 |
| 2019-07-02 | Genentech, Inc. | $1,122 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2019 |
| 2019-07-01 | Boston Scientific Corporation | $1,968 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE III | 2019 |
| 2019-07-01 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | Synergy Device, Stents | EVOLVE II | 2019 |
| 2019-06-27 | Penumbra, Inc. | $136 | Research payment | Cash or cash equivalent | Penumbra SMART Coil Device, Neurointervention | SMART Registry | 2019 |
| 2019-06-20 | Genentech USA, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-06-19 | Penumbra, Inc. | $4,470 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-06-11 | E.R. Squibb & Sons, L.L.C. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-05-30 | Genentech, Inc. | $365 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | A PHASE III STUDY IN COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN BRAFWT MELANOMA PATIENTS | 2019 |
| 2019-05-29 | Genentech, Inc. | $7,175 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2019 |
| 2019-05-23 | Genentech, Inc. | $564 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2019 |
| 2019-05-16 | Penumbra, Inc. | $2,193 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-05-08 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Ph III Copanlisib+Rituximab in relapsed iNHL | 2019 |
| 2019-05-07 | Genentech, Inc. | $280 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2019 |
| 2019-05-03 | Genentech USA, Inc. | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Activase Biological, Metabolism & Primary Care | 2019 | |
| 2019-05-02 | Roche Products Limited | $4,000 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | MORPHEUS PANCREATIC | 2019 |
| 2019-04-30 | CSL Behring | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-04-23 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2019 |
| 2019-04-18 | Genentech, Inc. | $11,918 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2019 |
| 2019-04-18 | Genentech USA, Inc. | $1,750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-04-17 | Janssen Pharmaceuticals, Inc | $700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-04-15 | Merit Medical Systems Inc | $3,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-04-12 | Genentech, Inc. | $21,191 | Research payment | Cash or cash equivalent | Zelboraf Biological, BioOncology | BRAF IN ADJUVANT | 2019 |
| 2019-04-11 | Penumbra, Inc. | $1,500 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-04-11 | Penumbra, Inc. | $500 | Research payment | Cash or cash equivalent | Penumbra SMART Coil Device, Neurointervention | SMART Registry | 2019 |
| 2019-04-04 | Genentech, Inc. | $8,444 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2019 |
| 2019-04-04 | Bayer Healthcare Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-04-01 | Bayer Healthcare Pharmaceuticals Inc. | $13,939 | Research payment | Cash or cash equivalent | Xarelto Drug, Cardio-pulmonary | Antithrombotic Therapy for TAVR: Rivaroxaban vs. Clopidogrel | 2019 |
| 2019-04-01 | Genentech, Inc. | $9,880 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2019 |
| 2019-03-28 | Penumbra, Inc. | $10,680 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-03-28 | Stryker Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SAGE N2T Device, MEDICAL | 2019 | |
| 2019-03-27 | Bayer Healthcare Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-03-19 | Merck Sharp & Dohme LLC | $1,750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-03-14 | Bayer Healthcare Pharmaceuticals Inc. | $6,500 | Research payment | Cash or cash equivalent | Non-Covered | Ph III Copanlisib+Rituximab in relapsed iNHL | 2019 |
| 2019-03-14 | Janssen Pharmaceuticals, Inc | $700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-03-12 | Bayer Healthcare Pharmaceuticals Inc. | $7,500 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-03-12 | Bayer Healthcare Pharmaceuticals Inc. | $4,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-03-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,750 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-03-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-03-07 | Bayer Healthcare Pharmaceuticals Inc. | $19,140 | Research payment | Cash or cash equivalent | Xarelto Drug, Cardio-pulmonary | Antithrombotic Therapy for TAVR: Rivaroxaban vs. Clopidogrel | 2019 |
| 2019-03-06 | E.R. Squibb & Sons, L.L.C. | $1,750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-03-01 | Genentech, Inc. | $10,278 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | A PHASE III STUDY IN COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN BRAFWT MELANOMA PATIENTS | 2019 |
| 2019-02-25 | Bayer Healthcare Pharmaceuticals Inc. | $6,000 | Research payment | Cash or cash equivalent | Non-Covered | Ph III Copanlisib+Rituximab in relapsed iNHL | 2019 |
| 2019-02-25 | Bayer Healthcare Pharmaceuticals Inc. | $5,750 | Research payment | Cash or cash equivalent | Non-Covered | Ph III Copanlisib+Rituximab in relapsed iNHL | 2019 |
| 2019-02-25 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Ph III Copanlisib+Rituximab in relapsed iNHL | 2019 |
| 2019-02-21 | Penumbra, Inc. | $10,832 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-02-14 | ACELL, INC. | $3,747 | Research payment | Cash or cash equivalent | Pelvic Organ Prolapse | 2019 | |
| 2019-02-07 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2019 | |
| 2019-02-06 | Bayer Healthcare Pharmaceuticals Inc. | $7,500 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-02-06 | Bayer Healthcare Pharmaceuticals Inc. | $4,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-02-06 | Bayer Healthcare Pharmaceuticals Inc. | $2,750 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-02-05 | Bayer Healthcare Pharmaceuticals Inc. | $46,068 | Research payment | Cash or cash equivalent | Xarelto Drug, Cardio-pulmonary | Antithrombotic Therapy for TAVR: Rivaroxaban vs. Clopidogrel | 2019 |
| 2019-02-04 | Bayer Healthcare Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-01-31 | Roche Products Limited | $1,000 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | MORPHEUS PANCREATIC | 2019 |
| 2019-01-17 | Penumbra, Inc. | $4,286 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2019 |
| 2019-01-17 | Penumbra, Inc. | $574 | Research payment | Cash or cash equivalent | Penumbra SMART Coil Device, Neurointervention | SMART Registry | 2019 |
| 2019-01-15 | TESARO, Inc. | $2,250 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | 2019 |
| 2019-01-09 | Merck Sharp & Dohme LLC | $1,750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | EMEND Drug, ONCOLOGY | 2019 | |
| 2019-01-03 | Genentech, Inc. | $13,401 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Summit, NJ, county Union County, NJ, state New Jersey; placed by its city name.
| Measure | Place (city or town) Summit, NJ | County Union County, NJ | State New Jersey |
|---|---|---|---|
| Population B01003 | 22,705 | 579,290 | 9,343,809 |
| Population, 2020 census P1 | 22,719 | 575,345 | 9,288,994 |
| Median age B01002 | 41.8 | 39.1 | 40.1 |
| Under 18 B01001 | 24.6% | 23.5% | 21.8% |
| 65 and over B01001 | 14.6% | 15.1% | 17.2% |
| Households B11001 | 8,341 | 203,277 | 3,507,701 |
| Foreign born B05002 | 18.8% | 33.6% | 23.9% |
| Median household income B19013 | $190,304 | $103,202 | $103,556 |
| Median family income B19113 | $250,001 | $125,330 | $127,025 |
| Per capita income B19301 | $112,787 | $52,874 | $54,253 |
| Poverty rate B17001 | 5.5% | 9.2% | 9.7% |
| Unemployment rate B23025 | 5.4% | 6.5% | 6.3% |
| Civilian labor force B23025 | 12,285 | 317,599 | 5,003,179 |
| Mean commute (minutes) B08013 | 33.5 | 30.2 | 30.5 |
| Bachelor's degree or higher B15003 | 72.5% | 38.9% | 43.6% |
| Housing units B25001 | 8,786 | 212,385 | 3,791,354 |
| Owner-occupied B25003 | 68.3% | 57.4% | 63.8% |
| Renters B25003 | 31.7% | 42.6% | 36.2% |
| Median home value B25077 | $994,500 | $529,200 | $454,400 |
| Median gross rent B25064 | $2,430 | $1,730 | $1,720 |
| White, not Hispanic B03002 | 67.1% | 35.4% | 50.9% |
| Black B03002 | 5.9% | 19.1% | 12.2% |
| Hispanic or Latino B03002 | 13.1% | 35.2% | 22.5% |
| Asian B03002 | 7.3% | 5.6% | 10.0% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Summit, NJ.
Comments